News

Filter

Current filters:

Oncologynivolumab

1 to 9 of 17 results

Bristol-Myers to file Opdivo BLA earlier than expected

Bristol-Myers to file Opdivo BLA earlier than expected

10-07-2014

Following discussions with the US Food and Drug Administration, Bristol-Myers Squibb is planning a third…

Bristol-Myers SquibbnivolumabOncologyOpdivoPharmaceuticalRegulationUSA

Bristol-Myers Ph III nivolumab trial stopped early on good results

Bristol-Myers Ph III nivolumab trial stopped early on good results

25-06-2014

Shares of US pharma major Bristol-Myers Squibb rose 2.6% to $49.55 in post-market trading on June 25,…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearch

Physicians views on EGFR wild-type/untested NSCLC treatment

Physicians views on EGFR wild-type/untested NSCLC treatment

20-06-2014

According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential…

AstraZenecaBiotechnologyBristol-Myers SquibbEuropeHealthcareMarkets & MarketingMerck & ConivolumabOncologyOno PharmaceuticalpembrolizumabselumetinibUSA

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

ASCO 2014: Strong results for Bristol-Myers Yervoy, and combo with nivolumab

ASCO 2014: Strong results for Bristol-Myers Yervoy, and combo with nivolumab

02-06-2014

Among the latest important research results presented at the 2014 prestigious annual meeting of the American…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearchYervoy

Bristol-Myers and Incyte sign up to evaluate combo regimen of two immunotherapies

27-05-2014

US pharma major Bristol-Myers Squibb and Incyte Corp have set up a clinical trial collaboration to evaluate…

Bristol-Myers SquibbINCB24360IncyteLicensingnivolumabOncologyPharmaceuticalResearch

Bristol-Myers’ nivolumab receives US FDA Breakthrough Therapy designation for Hodgkin lymphoma

15-05-2014

The US Food and Drug Administration has granted US drug major Bristol-Myers Squibb’s investigational…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalRegulationUSA

1 to 9 of 17 results

COMPANY SPOTLIGHT

Menarini

Back to top